Shorted

Emyria (EMD) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Neutral
just now

Why Is Emyria (ASX:EMD) Back in Cannabis Focus?

Highlights The clinical group has cleared a prescriber capacity bottleneck across its Western Australian and Queensland treatment sites. Newly recruited therapists largely meet revised regulator eligibility criteria, allowing additional dosing days to be scheduled. A fifth treatment clinic extends the network into New South Wales, giving national coverage across major states. A shift in sector emphasis is giving the latest update from Emyria (ASX:EMD) more context than the headline alone conv...

Continue reading
Kalkine
Neutral
just now

What Is Putting Emyria (ASX:EMD) in Focus?

Highlights Emyria reports sharply higher half-year revenue as patient numbers grow across its Emerald Clinics network. The company completes staff training ahead of opening a further specialist clinic focused on mental health and neurological conditions. Real-world patient data collected across the clinic network continues to feed the group's broader drug development pipeline. Emyria (ASX:EMD), the Perth-headquartered drug development company that also owns and operates the Emerald Clinics ne...

Continue reading
Kalkine
Neutral
just now

Why Is Emyria (ASX:EMD) Facing a Proof-First Market?

Highlights Australias cannabis sector is increasingly rewarding demonstrated commercial and clinical progress rather than ambitious narratives. Cost discipline and funding resilience now carry greater weight as companies manage capital-intensive operations. Revenue, prescriptions, product availability and clinical evidence have become the proof points separating stronger operators from weaker stories. Australias cannabis sector is entering a more demanding phase, and Emyria (ASX:EMD) sits...

Continue reading
Kalkine
Neutral
just now

Top ASX Cannabis Stock to Watch: Can Emyria (ASX:EMD) Stay Ahead as Rules Tighten?

Highlights Regulatory scrutiny is reshaping Australia's medicinal cannabis industry with stronger compliance requirements. Telehealth prescribing models are facing closer oversight as authorities tighten enforcement. Evidence-driven operators could gain an edge as compliance standards rise across the sector. Australia's medicinal cannabis sector is entering a defining phase as tighter regulatory oversight reshapes how businesses operate across the market. While sentiment in the broader Au...

Continue reading
Kalkine
Neutral
just now

Top Reasons Emyria (ASX:EMD) Is Expanding Beyond Cannabis Into Psychedelic Care

Highlights Emyria has secured a supply of clinical-grade MDMA to support supervised psychedelic-assisted therapy for a sizeable patient cohort. Australia's early regulatory framework for psychedelic medicines is helping the company build a clinically focused treatment model. The expansion strengthens Emyria's position within the ASX Cannabis Stocks category while broadening its healthcare offering. Australia's share market is ending the week against a backd...

Continue reading